Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand
Newsquawk Staff ·
Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand.
What it means
Pulling a niche product from a small export market is a recurring pattern in the auto sector and typically reflects the economics of low-volume variants rather than demand failure: right-hand-drive conversion, homologation, and compliance costs for markets of this size rarely clear the hurdle on a vehicle already built in limited numbers. For Tesla specifically, decisions of this kind have precedent in the company's history of announcing broad market availability at launch and then quietly narrowing scope, with prior form showing the order book and deposit holders get refunded or redirected rather than the programme being revived. The relevant distinction for the equity is between a regional withdrawal, which is immaterial to consolidated volumes, and a signal about the Cybertruck programme's overall unit economics, where the market has previously reacted more to cancellation of variants and price changes than to geographic trims. What tends to matter next is whether the decision is accompanied by commentary on global Cybertruck demand, reservation conversion rates, or production cadence at the plant level, since those reads carry the estimate risk rather than the Australia and New Zealand volumes themselves. Deposit refund language and any reallocation of that production to domestic deliveries are the usual follow-on tells.
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile
- US PREMARKET MOVERS: META, TSLA, IBM, LRCX, BX, PG, CMCSA, SAP, BABA
- US BROKER MOVES: CME upgraded at JPM; BROS downgraded at RBC
Related headlines
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone5 hours ago
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED7 hours ago
- State of Rhode Island sues Meta (META) over alleged tolerance for scam advertising8 hours ago
- Nvidia (NVDA) launches Minerva platform for end-to-end AI factory observability9 hours ago
- Meta's (META) 5yr CDS hits an all-time high at 114.5bps10 hours ago
- Google (GOOGL) is launching an agent compute engine11 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated2 hours ago
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)4 hours ago
- Uber (UBER) puts all 30,000 employees on ChatGPT Work8 hours ago
- Newsquawk Daily US Earnings Estimates - 23rd October 2026: AXP8 hours ago
- Fireblocks denies talks with Visa (V), CoinDesk reports9 hours ago
- Norfolk Southern (NSC) says tightening truck capacity is improving rail competitiveness, supporting truck-to-rail conversions and stronger customer demand10 hours ago
- Procter & Gamble (PG) CFO says 'so far, consumer has held up, we don't know if that's going to continue'10 hours ago
- eBay (EBAY) confirms plans to reduce workforce by 9%; expects Q3 results above guidance 11 hours ago
- AbbVie (ABBV) announces positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa11 hours ago